Navigation Links
Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
Date:2/15/2008

NEW YORK, Feb. 15 /PRNewswire/ -- Intra-Cellular Therapies, Inc. (ITI), announced the presentation of preclinical data on ITI-007, its first-in-class dual 5HT2A receptor antagonist/dopamine receptor phosphoprotein modulator (DPPM) for the treatment of schizophrenia, and ITI-002, ITI's family of compounds that inhibit a novel intracellular target for the treatment of cognitive dysfunction in schizophrenia. Data characterizing the pharmacological profile of these drug candidates were highlighted in an oral presentation given last week at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders. ITI-007 is currently in Phase I clinical trials for the treatment of schizophrenia.

"We believe the novel pharmacological properties of ITI-007 may provide new treatment alternatives with significant safety and patient compliance-related advantages over currently available therapies for the treatment of schizophrenia," said Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies. "In addition, we are developing ITI-002 to treat cognitive dysfunction in schizophrenia which remains an important quality of life issue for individuals with schizophrenia and is not addressed by current medications."

ITI-007 Study Results

In vitro, ITI-007 was shown to be a potent, sub-nanomolar, antagonist at 5HT2A receptors with a 60-fold higher affinity for 5HT2A receptors over D2 receptors. In vivo, ITI-007 produced an intracellular protein phosphorylation pattern consistent with the activity of a partial agonist at pre-synaptic D2 receptors. This pre-synaptic partial agonist activity preserves normal dopamine metabolism rather than causing a dramatic increase as seen with other antipsychotic therapies. Behaviorally, ITI-007 inhibited serotonin induced head twitches. Additionally, ITI-007 was shown to have an affinity for the serotonin reuptake site, an activity that potentially may be beneficial in treating affective disord
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
2. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
3. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
4. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
5. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
8. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
9. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 Discovery Laboratories, Inc. (Nasdaq: ... on developing aerosolized KL4 surfactant therapies for respiratory ... at 8:30 a.m. Eastern Time on Tuesday August 11, ... 2015 second quarter financial results along with providing ... press release announcing the second quarter 2015 financial ...
(Date:8/3/2015)... -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), a ... of innovative therapies for the treatment of acute pain, ... for the three and six months ended June 30, ... July 23, 2015, the Committee for Medicinal Products for ... for the management of acute moderate-to-severe post-operative pain in ...
(Date:8/3/2015)... FLINT, Mich., Aug. 3, 2015 Diplomat Pharmacy, Inc. ... announced financial results for the quarter ended June 30, 2015. ... June 30, 2014. Second Quarter 2015 Highlights ... of 49% or $266 million , Total prescriptions dispensed ... of 8.6% versus 5.5% , Adjusted EBITDA of $22.7 ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... 2010 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... quarter ended September 30, 2010, on Tuesday, November 9, 2010 ... Company recently held an investor conference call on October 11th, ... with the release of the Company,s third quarter results.  The ...
... The Phase 3 results from the ADVANCE study ... The study reports an improvement in treatment discontinuation rates ... and demonstrates an increase in sustained viral response (SVR) ... endpoint for this study was SVR 24 weeks after ...
Cached Medicine Technology:Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 2Increased SVR and Decreased Adverse Events Reported in Final Results of Phase 3 Study on Telaprevir 3
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is ... health conditions, pictures and medical art can be essential. StayWell, a health solutions company, ... Krames Patient Education solutions have been used by physicians and other health care providers ...
(Date:8/4/2015)... Farmingdale, New York (PRWEB) , ... August 04, ... ... for exceptional dietary supplement manufacturing, label design, product packaging, and fulfillment services, joined ... Workplace Challenge. The event was held on Tuesday, July 28th at Jones ...
(Date:8/4/2015)... Morristown & Montclair, NJ (PRWEB) , ... August 04, 2015 , ... ... certificate program in Arts and Health, the first of its kind in New Jersey, ... The University’s College of the Arts and Graduate School partnered with Atlantic Health System, ...
(Date:8/4/2015)... Las Vegas, Nevada (PRWEB) , ... August 04, ... ... INTIMATELY FEMALE, a striking contemporary look at unique artistic expressions from a diverse ... Motel inside the Life Is Beautiful Music & Art Festival on September 25-27, ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... brings an automatic end to driving, says the August 2015 Harvard Health Letter. ... okay to drive. It requires an individual assessment of skills," says Lissa Kapust, ...
Breaking Medicine News(10 mins):Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2
... artificial heart could prevent death in critically ill patients ... . The artificial heart implant improved survival rates before ... ,The artificial heart was found to be a ... did not improve with standard therapy and who were ...
... drug combined with sunlight helps the body tan quicker without ... that is similar to the body’s hormone that regulates skin ... can induce tanning in human volunteers who are known to ... Researchers conducted three different clinical trials to see if MT-1 ...
... research shows a significant improvement in treatment for a specific ... seminoma is typically treated by // removal of the testicle ... a second cancer in another organ up to 20 years ... a single course of the drug carboplatin and more than ...
... risk of developing a variety of skin conditions such ... many of these problems can be averted by correcting ... instrument. ,Researchers found the most common skin disorders ... of an instrument and irritations caused by prolonged, intense ...
... drug that helps reduce the risk of reactivating the ... with chemotherapy for breast cancer.An estimated 12 percent // ... and these patients are at risk of developing HBV ... in varying degrees of liver damage that may lead ...
... has shed light on how brain controls movement say researchers. ... make its whiskers twitch, a discovery researchers say //could help ... scientists develop devices paralyzed people could control, such as robotic ... the part of the brain that controls movement contains so ...
Cached Medicine News:
This popular post op shoe provides quality care at an outstanding value. The semi-rigid outsole provides stability and minimizes flexure....
... Specifically designed for patients who experience severe ... Day prevents tears in fibrous tissue that ... during those first steps in the morning. ... the pain associated with plantar fasciitis and ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Resilient insole has a series of removable hexagons for tailored pressure relief....
Medicine Products: